$0.16
0.00 (-1.23%)
Open$0.16
Previous Close$0.16
Day High$0.16
Day Low$0.16
52W High$19.20
52W Low—
Volume—
Avg Volume5.15M
Market Cap3.15M
P/E Ratio—
EPS$-4.00
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+29,906.2% upside
Current
$0.16
$0.16
Target
$48.34
$48.34
$29.39
$48.34 avg
$58.89
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.75M | 1.85M | 1.56M |
| Net Income | -488,923 | -548,272 | -518,591 |
| Profit Margin | -27.9% | -29.7% | -33.3% |
| EBITDA | -843,788 | -899,520 | -655,593 |
| Free Cash Flow | -343,922 | -223,177 | -234,743 |
| Rev Growth | +4.0% | +6.5% | +13.9% |
| Debt/Equity | 0.91 | 0.97 | 0.83 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.53 | -1.09% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $361.16 | +0.17% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.13 | -0.16% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $494.74 | -0.98% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $628.06 | -0.59% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $297.43 | +1.33% | 69.3 | 39.97B |